Religious Fasting of Muslim Patients After Metabolic and Bariatric Surgery: a Modified Delphi Consensus

Abstract Background Hair loss is a common complication after metabolic and bariatric surgery (MBS). There is a lack of published systematic review in the scientific literature on this topic. The aim of this study was to perform a systematic review and meta-analysis on hair loss after MBS in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines. Methods PubMed, CINAHL, EMBASE, Web of Science, SCOPUS, and four Chinese databases were searched. Data were pooled using Review Manager 5.3 and Stata 12.0, and subgroups were performed if necessary and feasible. Results A total of 18 studies (n = 2538) were included. The pooled results showed that the incidence of hair loss after MBS was 57% (95% CI 42–71%). It decreased with longer follow-up times. Hair loss was significantly more common in younger (mean difference (MD), − 2.45; 95% CI, − 4.26 to − 0.64; p = 0.008) women (OR, 3.87; 95% CI, 0.59 to 17.59; p = 0.08). Serum zinc (standardized mean difference (SMD), − 1.13; 95% CI, − 2.27 to 0.01, p = 0.05), folic acid (SMD = − 0.88, 95% CI − 1.29 to − 0.46, p < 0.0001), and ferritin levels (SMD, − 0.22; 95% CI, − 0.38 to − 0.05; p = 0.01), but not serum iron and vitamin B12, were associated with hair loss following MBS. Conclusions Hair loss is common after MBS especially in younger women, and those with low serum levels of zinc, folic acid, and ferritin. Prospective studies on larger cohorts are needed.

Download Full-text

Intersection of smoking, e-cigarette use, obesity, and metabolic and bariatric surgery: a systematic review of the current state of evidence

Journal of Addictive Diseases ◽

10.1080/10550887.2021.1874817 ◽

2021 ◽

pp. 1-19

Author(s):

Nimisha Srikanth ◽

Luyu Xie ◽

Elisa Morales-Marroquin ◽

Ashley Ofori ◽

Nestor de la Cruz-Muñoz ◽

...

Keyword(s):

Systematic Review ◽

Bariatric Surgery ◽

Cigarette Use ◽

Current State ◽

Metabolic And Bariatric Surgery

Download Full-text

Aromatic L-amino Acid Decarboxylase (AADC) deficiency: results from an Italian modified Delphi consensus

Italian Journal of Pediatrics ◽

10.1186/s13052-021-00954-4 ◽

2021 ◽

Vol 47 (1) ◽

Cited By ~ 1

Author(s):

Carlo Fusco ◽

◽

Vincenzo Leuzzi ◽

Pasquale Striano ◽

Roberta Battini ◽

...

Keyword(s):

Amino Acid ◽

Diagnostic Delay ◽

Steering Committee ◽

Outcome Data ◽

Diagnosis And Treatment ◽

Acid Decarboxylase ◽

Delphi Consensus ◽

Amino Acid Decarboxylase ◽

Modified Delphi ◽

Number Of Patients

Abstract Background Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare and underdiagnosed neurometabolic disorder resulting in a complex neurological and non-neurological phenotype, posing diagnostic challenges resulting in diagnostic delay. Due to the low number of patients, gathering high-quality scientific evidence on diagnosis and treatment is difficult. Additionally, based on the estimated prevalence, the number of undiagnosed patients is likely to be high. Methods Italian experts in AADC deficiency formed a steering committee to engage clinicians in a modified Delphi consensus to promote discussion, and support research, dissemination and awareness on this disorder. Five experts in the field elaborated six main topics, each subdivided into 4 statements and invited 13 clinicians to give their anonymous feedback. Results 100% of the statements were answered and a consensus was reached at the first round. This enabled the steering committee to acknowledge high rates of agreement between experts on clinical presentation, phenotypes, diagnostic work-up and treatment strategies. A research gap was identified in the lack of standardized cognitive and motor outcome data. The need for setting up an Italian working group and a patients’ association, together with the dissemination of knowledge inside and outside scientific societies in multiple medical disciplines were recognized as critical lines of intervention. Conclusions The panel expressed consensus with high rates of agreement on a series of statements paving the way to disseminate clear messages concerning disease presentation, diagnosis and treatment and strategic interventions to disseminate knowledge at different levels. Future lines of research were also identified.

Download Full-text

Update on pediatric metabolic and bariatric surgery

Pediatric Obesity ◽

10.1111/ijpo.12794 ◽

2021 ◽

Author(s):

Dani O. Gonzalez ◽

Marc P. Michalsky

Keyword(s):

Bariatric Surgery ◽

Metabolic And Bariatric Surgery

Download Full-text

Vaccinations in patients with multiple sclerosis: A Delphi consensus statement

Multiple Sclerosis Journal ◽

10.1177/1352458520952310 ◽

2020 ◽

pp. 135245852095231 ◽

Cited By ~ 1

Author(s):

Agostino Riva ◽

Valeria Barcella ◽

Simone V Benatti ◽

Marco Capobianco ◽

Ruggero Capra ◽

...

Keyword(s):

Multiple Sclerosis ◽

Seasonal Influenza ◽

Careful Consideration ◽

Delphi Consensus ◽

Consensus Process ◽

Disease Modifying Drugs ◽

Risks And Benefits ◽

Modified Delphi ◽

Increased Risk ◽

Evidence Based Decision Making

Background: Patients with multiple sclerosis (MS) are at increased risk of infection. Vaccination can mitigate these risks but only if safe and effective in MS patients, including those taking disease-modifying drugs. Methods: A modified Delphi consensus process (October 2017–June 2018) was used to develop clinically relevant recommendations for making decisions about vaccinations in patients with MS. A series of statements and recommendations regarding the efficacy, safety and timing of vaccine administration in patients with MS were generated in April 2018 by a panel of experts based on a review of the published literature performed in October 2017. Results: Recommendations include the need for an ‘infectious diseases card’ of each patient’s infectious and immunisation history at diagnosis in order to exclude and eventually treat latent infections. We suggest the implementation of the locally recommended vaccinations, if possible at MS diagnosis, otherwise with vaccination timing tailored to the planned/current MS treatment, and yearly administration of the seasonal influenza vaccine regardless of the treatment received. Conclusion: Patients with MS should be vaccinated with careful consideration of risks and benefits. However, there is an urgent need for more research into vaccinations in patients with MS to guide evidence-based decision making.

Download Full-text